Antibiotics belonging to the category of tetracyclines have been widely used in periodontal therapy due to their specifi c characteristics that makes them eff ective both against the microorganisms responsible of the periodontal disease and against the enzymatic products responsible of the periodontal breakdown. A search of the recent literature (January 2009-December 2014) was conducted in order to make a review of the use of tetracyclines for local use in periodontal therapy. From this review we can infer that the use of local tetracyclines brings signifi cant advantages in periodontal therapy. However, to date, it is not possible to establish guidelines on the use of these agents given the heterogeneity in the protocols used in the various studies and the lack of a consensus accepted by the scientifi c community. The local locally delivered tetracyclines is eff ective in the treatment of periodontal disease when used in addition to the mechanical therapy and is particularly eff ective in cases of localized acute lesions or individual sites unresponsive to the causal therapy.
Introduction
Periodontitis is a multifactorial infl ammatory disease with a bacterial etiology, characterized by loss of periodontal attachment and bone destruction and is associated with several risk factors. [1, 2] Despite more than 700 bacterial species have been identifi ed in the oral microbiota, only a small group of 10-15 species are signifi cantly involved in the beginning and progression of periodontal diseases, among which Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Prevotella intermedia, Tannerella forsythensis, and Treponema denticola are the most common. [3] Among the tissue destruction mechanisms implicated in the pathogenesis of periodontal disease, of particular importance is the action of proteolytic enzymes (released by periodontopathogens and from host defenses) such as matrix metalloproteases (MMPs), which have as main target of their destructive activity the collagene. [4] The objective of the initial periodontal treatment is the reestablishment of the biological compatibility of the root surfaces aff ected by periodontal disease, in order to stop the progression of the disease. The non-surgical therapy seeks to remove from the tooth surface and the adjacent soft tissues both the living bacteria hosted in the biofi lm and the microbial organisms in the calcifi ed biofi lm. The non-surgical therapy, while showing signifi cant long-term success in periodontal treatment of most of the patients, presents some limitations as the diffi culty to reach deep sites, winding pockets or furcation involvements, and the inability to remove bacteria from the dentinal tubules, lacunae, root hollows, and soft tissues. Antibiotic therapy may therefore be of considerable aid when used in addition to the mechanical therapy.
The systemic antibiotic therapy, mainly indicated in aggressive generalized conditions, has limitations and drawbacks such as the low concentration in the gingival crevicular fl uid (GCF) and in the periodontal tissues, the induction of bacterial resistance, the possible systemic toxicity. [5] Given the disadvantages of systemic therapy and the specifi c indication in aggressive conditions, while not being an alternative to scaling and root planing (SRP), there are localized forms of periodontitis wherein topical antibiotic delivery can be used in addition to SRP. Although there are no detailed guidelines, the main indications are represented by deep active sites and sites with recurrent probing depth (PD) greater than or equal to 5 mm. In these situations, the overall eff ect of the application of the subgingival antimicrobials is statistically signifi cant greater, in terms of PD and clinical attachment level (CAL) compared to the SRP alone. The benefi t in the reduction of PD is most evident with the use the antibiotics of the tetracycline class. [6] 
Tetracyclines
Tetracyclines are bacteriostatic antibiotics with broad spectrum, therefore eff ective both on Gram-negative and on Gram-positive, aerobic and anaerobic bacteria. They include tetracycline, minocycline, and doxycycline.
Most of the subgingival microorganisms are susceptible to tetracycline at a concentration of less than 1-2 μg/mL. The minimum inhibitory concentration required to inhibit the growth of 90% of the strains is less than 6 μg/mL. [7] Unlike other antimicrobial agents, as amply demonstrated by clinical studies and in animals, tetracyclines are able to directly inhibit MMPs, and collagenases expressed by immune cells of the host and by microorganisms. [8, 9] Finally, doxycycline in particular has shown positive eff ects by stimulating the maturation and diff erentiation of osteoblast cell, increasing the activity of alkaline phosphatase, thus expounding an important eff ect on the periodontal regeneration.
Tetracycline
Normally, the topical administration of tetracycline in the pharmaceutical formulation in fi bers. The application of subgingival fi bers of tetracycline has showed relatively high concentrations of antibiotic in the GCF for 10 days. [11] Patients who receive this type of adjunctive therapies with SRP can benefi t from the application of topical tetracycline especially in the maintenance phase to 12 months of treatment, generally showing a modest gain in clinical attachment (CAL gain) and/or reduction of PD, when compared to SRP alone. [12] Sachdeva and Agarwal, however, revealed that the use of combination therapy is actually more eff ective than SRP alone in improving the clinical parameters of plaque index (PI), gingival index (GI), PD, and CAL, anyway they only reported results at 3 months follow-up. [13] An alternative to the use of the fi bers of tetracycline is the application of a solution of tetracycline via microbrush, especially in sites where it is not recommended a vigorous mechanical therapy during maintenance programs, with a more favorable cost/benefi t ratio for the patient. [14] 
Minocycline
The release of subgingival minocycline has been studied in diff erent forms. Applying a gel of minocycline in addition to SRP was eff ective in reducing the PD in sites with moderate to severe periodontal disease, although a recent study showed a statistically signifi cant diff erence compared to the control represented by SRP alone. [15, 16] Currently, the topical formulation which is more used is a product with physical properties of a powder and consists of resorbable microspheres of minocycline. The eff ectiveness of the use of resorbable microspheres of minocycline (Arestin; OraPharma, Horsham, PA, USA) was evaluated in a split mouth randomized clinical trial on 60 sites in 15 patients with chronic periodontitis. [17] In each patient, two sites were treated with only the SRP and two sites were treated with the microspheres of minocycline in addition to the SRP. A signifi cant reduction in all parameters considered (PI, GI, gingival bleeding index; PD) was observed in the test group after 6 months of follow-up. These results were confi rmed in a recent study by Bland et al. [18] in which, at 30 days from the baseline, the use of minocycline microspheres in addition to the SRP has determined a statistically signifi cant improvement in all the clinical parameters considered (PD, Bleeding on Probing [BoP] CAL) and all the microbiological endpoints defi ned as reduction in the proportions and in the number of bacteria of the red complex (Tannerella forsythensis, Porphyromonas gingivalis, Treponema denticola). The reduction of these bacterial species is signifi cantly related to a reduction of PD, especially as regards T. forsythensis.
In another study, it was demonstrated the superiority of topical therapy with minocycline microspheres in addition to SRP in signifi cantly improving the CAL when compared to treatment with metronidazole gel 25% + SRP, or simple SRP after 3 months of follow-up. [19] 
Doxycycline
Numerous clinical studies have demonstrated the effi cacy of controlled-release systems containing doxycycline when used in addition to SRP. [20, 21] The local delivery device used most often is the topical formulations of doxycycline gel, usually 10% (Atridox; Block Drug, Jersey City, NJ, US) or 14% (Ligosan Slow Release ® ; Heraeus Kulzer GmbH, Germany).
The clinical effi cacy of both doxycycline gels, evaluated in terms of gain in clinical attachment in periodontal pockets, as well as their pharmacokinetics in GCF and saliva, has been investigated in several studies. [22, 23] The eff ectiveness of 10% topical doxycycline has been recently assessed in a clinical study on 60 sites (with PD between 5 and 7 mm) in 60 patients with chronic periodontitis. [24] Thirty patients were treated with 10% topical doxycycline + SRP while the remaining 30 with SRP + placebo containing glycerin. At 6 months from treatment, in deep pockets (>5 mm), statistically signifi cant diff erences were observed between the two groups in favor of the test group as regards the average reduction of PD as well as regards the value of CAL-gain. For 5 mm pockets, there were no signifi cant diff erences between the test group and the control.
Similarly, another recent study has shown that there are signifi cant diff erences between the combination therapy and the SRP alone in the treatment of PD with pockets between 5 and 7 mm. The authors also claim that the application of topical
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Locally delivered tetracyclines and periodontal therapy doxycycline 10% alone is equally eff ective to SRP alone in reducing the clinical signs of periodontitis from baseline to 3 months; however, the study presents a limited number of patients. [25] The eff ects of a single topical application of 14% doxycycline in addition to the SRP, in patients with persistent/recurrent periodontitis, were analyzed in a randomized multicenter clinical trial, comparing them with the simple mechanical therapy. [26] A signifi cant eff ect in the reduction of PD at 3 months was observed only for pockets with initial depth greater than or equal to 5 mm; a benefi cial eff ect was observed at 6 months for 6 mm pockets; no benefi t was observed at 12 months.
Two diff erent studies have also evaluated the use of these two formulations containing doxycycline at diff erent concentrations, as an adjunct to SRP in the treatment of multi-rooted elements with furcation involvements. [27, 28] One of these two studies showed that, despite the local antibiotic therapy in addition to SRP can make a modest benefi t in the short term (3 months) in helping to slow the progression of furcation involved, and sometimes signifi cantly reduce the horizontal loss of attachment compared to the SRP alone, there are no statistically signifi cant diff erences at 6 and 12 months between the two therapies. [27] The second study has clearly demonstrated that combination therapy does not bring signifi cant benefi ts in reducing the degree of involvement of furcations than the simple non-surgical debridement. [28] Two other studies have investigated further controlled release systems of doxicycline. [29, 30] One study compared doxicycline "biodegradable implants" (polymer fi lms based on poly-epsiloncaprolactone dissolved in dichloromethane and carbopol containing 60 mg of doxycycline hyclate) with a gel containing 25 mg of doxycycline which in contact with the GCF, allows a controlled release of the drug. [29] Thirty patients with chronic periodontitis with residual pockets greater than or equal to 5 mm were divided into three groups 2 weeks after causal therapy: The fi rst group received the application of doxycycline gel, the second the biodegradable implants, and the third only SRP. Both groups of patients who received the drug treatment showed reductions of local PI, GI, PD, and CAL gain 90 days after initiation of therapy compared to the control group. Another study, however, has fi rst tested in vitro, and then in vivo, the effi cacy of the microspheres of doxycycline in patients with chronic periodontitis. [30] Fourteen patients were randomly assigned to two groups of 7 patients each. All patients received one session of SRP in full mouth; the control group received the application of microspheres doxycycline only at baseline, while the group tests at baseline, at 1 month and 3 months. At 6 months from baseline, the test group showed a statistically signifi cant reduction of PD compared to the control group; other outcomes considered in the following study, relative attachment level, BOP and PI, showed no signifi cant diff erences between the two groups.
Conclusions
The analysis of the current evidence shows heterogeneous results, in part due to the diff erent protocols used in the studies, with clear diff erences in target populations, methods of study design and duration. The lack of uniformity in the use of protocols adopted in studies on these devices could challenge their real validity, although there are studies in which the benefi t is clearly demonstrated.
In conclusion, many studies in the literature report encouraging results about the use of locally delivered tetracyclines, there aren't, however, suffi cient evidence to support well-defi ned protocols or dosages to apply in certain clinical conditions. It is therefore necessary to defi ne a consensus concerning the establishment of shared guidelines that can guide the clinician in selecting and using the diff erent products available on the market today.
